A clinical trial has found that treatment with the immunomodulator interferon beta-1a plus the antiviral remdesivir was not superior to treatment with remdesivir alone in hospitalized adults with COVID-19 pneumonia. In addition, in a subgroup of patients who required high-flow oxygen, investigators found that interferon beta-1a was associated with more adverse events and worse outcomes.
from Latest Science News -- ScienceDaily https://www.sciencedaily.com/releases/2021/10/211018183349.htm
from Latest Science News -- ScienceDaily https://www.sciencedaily.com/releases/2021/10/211018183349.htm
Interferon does not improve outcomes for hospitalized adults with COVID-19, clinical trial finds
![Interferon does not improve outcomes for hospitalized adults with COVID-19, clinical trial finds]()
Reviewed by cmakigo
on
October 19, 2021
Rating:
No comments:
Post a Comment